

Suzanne M Cadarette

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6503729/publications.pdf>

Version: 2024-02-01

92
papers

3,687
citations

117625
34
h-index

138484
58
g-index

92
all docs

92
docs citations

92
times ranked

4812
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect. <i>American Journal of Epidemiology</i> , 2007, 166, 348-354.	3.4	321
2	Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 950-956.	5.0	318
3	The three-year incidence of fracture in chronic kidney disease. <i>Kidney International</i> , 2014, 86, 810-818.	5.2	189
4	Evaluation of Decision Rules for Referring Women for Bone Densitometry by Dual-Energy X-ray Absorptiometry. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 57.	7.4	170
5	Physician Follow-up and Provider Continuity Are Associated With Long-term Medication Adherence. <i>Archives of Internal Medicine</i> , 2007, 167, 847.	3.8	158
6	Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. <i>Osteoporosis International</i> , 2013, 24, 659-669.	3.1	124
7	An Introduction to Health Care Administrative Data. <i>Canadian Journal of Hospital Pharmacy</i> , 2015, 68, 232-7.	0.1	109
8	The Economic Impact of Clostridium difficile Infection: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2015, 110, 511-519.	0.4	107
9	Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process. <i>Osteoporosis International</i> , 2003, 14, 672-676.	3.1	93
10	A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2792-2798.	3.6	86
11	The validity of decision rules for selecting women with primary osteoporosis for bone mineral density testing. <i>Osteoporosis International</i> , 2004, 15, 361-366.	3.1	85
12	Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture. <i>Annals of Internal Medicine</i> , 2008, 148, 637.	3.9	82
13	Is There a Relationship Between Patient Beliefs or Communication About Generic Drugs and Medication Utilization?. <i>Medical Care</i> , 2009, 47, 319-325.	2.4	76
14	Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. <i>Journal of Rheumatology</i> , 2008, 35, 319-26.	2.0	63
15	How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs. <i>Canadian Family Physician</i> , 2003, 49, 462-8.	0.4	60
16	Osteoporosis treatments and adverse events. <i>Current Opinion in Rheumatology</i> , 2009, 21, 363-368.	4.3	59
17	The Complex Relation between Bisphosphonate Adherence and Fracture Reduction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3251-3259.	3.6	58
18	Access to Osteoporosis Treatment is Critically Linked to Access to Dual-Energy X-ray Absorptiometry Testing. <i>Medical Care</i> , 2007, 45, 896-901.	2.4	55

#	ARTICLE	IF	CITATIONS
19	The Association between Statin use and Outcomes Potentially Attributable to an Unhealthy Lifestyle in Older Adults. <i>Value in Health</i> , 2011, 14, 513-520.	0.3	55
20	Placebo Adherence, Clinical Outcomes, and Mortality in the Women's Health Initiative Randomized Hormone Therapy Trials. <i>Medical Care</i> , 2011, 49, 427-435.	2.4	55
21	The impact of pharmacist interventions on osteoporosis management: a systematic review. <i>Osteoporosis International</i> , 2011, 22, 2587-2596.	3.1	48
22	Confounder summary scores when comparing the effects of multiple drug exposures. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 2-9.	1.9	47
23	Caseâ€crossover study design in pharmacoepidemiology: systematic review and recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1146-1153.	1.9	47
24	Oral bisphosphonate use in the elderly is not associated with acute kidney injury. <i>Kidney International</i> , 2012, 82, 903-908.	5.2	46
25	Factors Associated With Complications of <i>Clostridium difficile</i> Infection in a Multicenter Prospective Cohort. <i>Clinical Infectious Diseases</i> , 2015, 61, 1781-1788.	5.8	46
26	Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 419-429.	2.8	45
27	Disease risk score as a confounder summary method: systematic review and recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 122-129.	1.9	44
28	Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. <i>Archives of Osteoporosis</i> , 2018, 13, 30.	2.4	43
29	Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013. <i>Canadian Pharmacists Journal</i> , 2016, 149, 293-302.	0.8	42
30	Comparative gastrointestinal safety of weekly oral bisphosphonates. <i>Osteoporosis International</i> , 2009, 20, 1735-1747.	3.1	41
31	Fracture Risk in Living Kidney Donors: A Matched Cohort Study. <i>American Journal of Kidney Diseases</i> , 2012, 59, 770-776.	1.9	40
32	Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. <i>Osteoporosis International</i> , 2012, 23, 1075-1082.	3.1	40
33	Minimal error in self-report of having had DXA, but self-report of its results was poor. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 1306-1311.	5.0	39
34	Measuring and improving adherence to osteoporosis pharmacotherapy. <i>Current Opinion in Rheumatology</i> , 2010, 22, 397-403.	4.3	38
35	Control yourself: <scp>ISPEâ€cendorsed</scp> guidance in the application of <scp>selfâ€controlled</scp> study designs in pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 671-684.	1.9	36
36	Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. <i>Osteoporosis International</i> , 2011, 22, 943-954.	3.1	34

#	ARTICLE	IF	CITATIONS
37	The lifetime cost of spinal cord injury in Ontario, Canada: A population-based study from the perspective of the public health care payer. <i>Journal of Spinal Cord Medicine</i> , 2019, 42, 184-193.	1.4	34
38	Osteoporosis quality indicators using healthcare utilization data. <i>Osteoporosis International</i> , 2011, 22, 1335-1342.	3.1	31
39	Bisphosphonates and risk of atrial fibrillation: a meta-analysis. <i>Arthritis Research and Therapy</i> , 2010, 12, R30.	3.5	30
40	Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 67-74.	1.9	26
41	Psychometric properties of the "Osteoporosis and You" questionnaire: osteoporosis knowledge deficits among older community-dwelling women. <i>Osteoporosis International</i> , 2007, 18, 981-989.	3.1	25
42	Design choices for observational studies of the effect of exposure on disease incidence. <i>BMJ Open</i> , 2019, 9, e031031.	1.9	25
43	Osteoporosis Health Belief Scale: Minor changes were required after telephone administration among women. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 154-166.	5.0	24
44	Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making. <i>Journal of Clinical Medicine</i> , 2021, 10, 1140.	2.4	23
45	Correlates of Forearm Bone Mineral Density in Young Norwegian Women: The Nord-Trondelag Health Study. <i>American Journal of Epidemiology</i> , 2002, 156, 418-427.	3.4	22
46	Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. <i>Osteoporosis International</i> , 2012, 23, 1475-1480.	3.1	22
47	Improvements in osteoporosis testing and care are found following the wide scale implementation of the Ontario Fracture Clinic Screening Program. <i>Medicine (United States)</i> , 2017, 96, e9012.	1.0	22
48	A population-based matched cohort study examining the mortality and costs of patients with community-onset <i>Clostridium difficile</i> infection identified using emergency department visits and hospital admissions. <i>PLoS ONE</i> , 2017, 12, e0172410.	2.5	22
49	Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012. <i>Osteoporosis International</i> , 2015, 26, 2845-2852.	3.1	21
50	The Economic Burden of Hospital-Acquired <i>Clostridium difficile</i> Infection: A Population-Based Matched Cohort Study. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1068-1078.	1.8	21
51	Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in Ontario. <i>BMC Health Services Research</i> , 2016, 16, 666.	2.2	21
52	Patient and Physician Predictors of Post-Fracture Osteoporosis Management. <i>Journal of General Internal Medicine</i> , 2008, 23, 1447-1451.	2.6	19
53	Development of an integrated-care delivery model for post-fracture care in Ontario, Canada. <i>Osteoporosis International</i> , 2006, 17, 1337-1345.	3.1	16
54	Initial uptake of the Ontario Pharmacy Smoking Cessation Program. <i>Canadian Pharmacists Journal</i> , 2015, 148, 29-40.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Diffusion of Innovations model helps interpret the comparative uptake of two methodological innovations: co-authorship network analysis and recommendations for the integration of novel methods in practice. <i>Journal of Clinical Epidemiology</i> , 2017, 84, 150-160.	5.0	16
56	Osteoporosis management among chronic glucocorticoid users: a systematic review. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2014, 21, e486-504.	1.4	14
57	Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 149-162.	2.5	13
58	Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 478-487.	2.8	13
59	Characteristics of patients vaccinated against influenza in physician offices versus pharmacies and predictors of vaccination location: a cross-sectional study. <i>CMAJ Open</i> , 2019, 7, E421-E429.	2.4	12
60	Variation in the days supply field for osteoporosis medications in Ontario. <i>Archives of Osteoporosis</i> , 2013, 8, 128.	2.4	11
61	Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study. <i>British Journal of Cancer</i> , 2018, 119, 1421-1427.	6.4	11
62	Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015. <i>Canadian Journal of Diabetes</i> , 2019, 43, 179-185.e1.	0.8	11
63	Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap. <i>Osteoporosis International</i> , 2019, 30, 1865-1872.	3.1	11
64	Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes. <i>Osteoporosis International</i> , 2019, 30, 2311-2319.	3.1	11
65	The Use of Active Comparators in Self-Controlled Designs. <i>American Journal of Epidemiology</i> , 2021, 190, 2181-2187.	3.4	11
66	Predictors of locating women six to eight years after contact: internet resources at recruitment may help to improve response rates in longitudinal research. <i>BMC Medical Research Methodology</i> , 2007, 7, 22.	3.1	10
67	Increased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UK. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2551-2561.	2.4	10
68	Five-year refracture rates of a province-wide fracture liaison service. <i>Osteoporosis International</i> , 2019, 30, 1671-1677.	3.1	10
69	Over half of seniors who start oral bisphosphonate therapy are exposed for 3 or more years: novel rolling window approach and patterns of use. <i>Osteoporosis International</i> , 2021, 32, 1413-1420.	3.1	10
70	Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy. <i>Annals of Internal Medicine</i> , 2022, 175, 335-343.	3.9	10
71	External validation of clinical prediction rules for complications and mortality following <i>Clostridioides difficile</i> infection. <i>PLoS ONE</i> , 2019, 14, e0226672.	2.5	9
72	Measuring patient perceptions about osteoporosis pharmacotherapy. <i>BMC Research Notes</i> , 2009, 2, 133.	1.4	8

#	ARTICLE	IF	CITATIONS
73	Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study. CMAJ Open, 2013, 1, E97-E105.	2.4	8
74	History and publication trends in the diffusion and early uptake of indirect comparison meta-analytic methods to study drugs: animated coauthorship networks over time. BMJ Open, 2018, 8, e019110.	1.9	8
75	Fracture prevalence and treatment with bone-sparing agents: are there urban-rural differences? A population based study in Ontario, Canada. Journal of Rheumatology, 2005, 32, 550-8.	2.0	7
76	Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study. CMAJ Open, 2015, 3, E91-E96.	2.4	6
77	High-Risk Patients' Readiness to Undergo BMD Testing for Osteoporosis Diagnosis in Pennsylvania. International Quarterly of Community Health Education, 2009, 29, 223-240.	0.9	5
78	The Burden of Osteoporosis in Canada. Canadian Pharmacists Journal, 2011, 144, S3-S3.e1.	0.8	5
79	Impact of the 2016 Policy Change on the Delivery of MedsCheck Services in Ontario: An Interrupted Time-Series Analysis. Pharmacy (Basel, Switzerland), 2019, 7, 115.	1.6	5
80	Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario. Addiction, 2019, 114, 268-277.	3.3	5
81	Lifetime cost of chronic ulcers requiring hospitalization in Ontario, Canada: A population-based study. Wound Medicine, 2018, 20, 21-34.	2.7	4
82	Osteoporosis management and fractures in the MAÛtis of Ontario, Canada. Archives of Osteoporosis, 2015, 10, 12.	2.4	3
83	The Ontario Pharmacy Evidence Network Interactive Atlas of Professional Pharmacist Services. Canadian Pharmacists Journal, 2021, 154, 153-159.	0.8	3
84	Urbanâ€rural differences in the uptake of new oral bisphosphonate formulations. Archives of Osteoporosis, 2016, 11, 11.	2.4	2
85	The Ontario Pharmacy Evidence Network Atlas of Community Pharmacy Influenza Immunizations. Canadian Pharmacists Journal, 2021, 154, 305-311.	0.8	2
86	Le fardeau de l'ostÃ©oporse au Canada. Canadian Pharmacists Journal, 2011, 144, S3-S3.e1.	0.8	2
87	Fracture outcome definitions in observational osteoporosis drug effects studies. JBI Evidence Synthesis, 2021, Publish Ahead of Print, .	1.3	1
88	The Ontario Pharmacy Evidence Network Atlas of MedsCheck services. Canadian Pharmacists Journal, 2022, 155, 171516352210804.	0.8	1
89	Performance of the disease risk score in a cohort study with policy-induced selection bias. Journal of Comparative Effectiveness Research, 2015, 4, 607-614.	1.4	0
90	Strategies for measuring prescription medication switching with pharmacy claims data: a scoping review protocol. JBI Evidence Synthesis, 2021, 19, 2441-2456.	1.3	0

#	ARTICLE	IF	CITATIONS
91	Observational study methods used to assess pharmacotherapy effects of type 2 diabetes on fracture risk: a scoping review protocol. JBI Evidence Synthesis, 2021, 19, 3129-3141.	1.3	0
92	The Ontario Pharmacy Evidence Network Atlas of Smoking Cessation Services. Canadian Pharmacists Journal, 0, , 171516352211013.	0.8	0